Aprepitant: drug-drug interactions in perspective

Area of Science:

• Oncology
• Pharmacology
• Drug Interactions

Background:

• Chemotherapy-induced nausea and vomiting (CINV) significantly impacts patient quality of life.
• Aprepitant is a neurokinin-1 receptor antagonist used to prevent CINV.
• Concerns exist regarding aprepitant's potential drug-drug interactions due to its inhibition of cytochrome P-450 3A4 (CYP3A4).

Purpose of the Study:

• To evaluate the clinical relevance of aprepitant's drug-drug interactions with commonly used chemotherapeutic agents and antiemetics.
• To assess the safety and efficacy of aprepitant in the context of potential interactions.

Main Methods:

• Review of existing literature and clinical data on aprepitant and its interactions.
• Analysis of interaction profiles with specific chemotherapeutic agents (e.g., cyclophosphamide, docetaxel, vinorelbine) and 5-HT3 antagonists (e.g., granisetron, ondansetron, palonosetron).

Main Results:

• No clinically relevant interactions were observed between aprepitant and the evaluated chemotherapeutic agents or 5-HT3 antagonists.
• Potential interactions with certain drugs, like warfarin, require monitoring, and corticosteroid doses may need adjustment.
• The concern regarding negative interactions with CYP3A4-metabolized agents is largely theoretical.

Conclusions:

• Aprepitant can be safely used for CINV prevention with minimal clinically significant drug-drug interactions.
• Management strategies exist for identified interactions, ensuring patient safety.
• Further investigation is needed for new agents extensively metabolized by CYP3A4.